

Chantal Housset

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/702846/publications.pdf>

Version: 2024-02-01

43
papers

1,434
citations

361296

20
h-index

360920

35
g-index

43
all docs

43
docs citations

43
times ranked

2041
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis. <i>Gut</i> , 2020, 69, 92-102. | 6.1 | 136 |
| 2 | Characterization of animal models for primary sclerosing cholangitis (PSC). <i>Journal of Hepatology</i> , 2014, 60, 1290-1303. | 1.8 | 129 |
| 3 | Genotype-phenotype relationships in the low-phospholipid-associated cholelithiasis syndrome: A study of 156 consecutive patients. <i>Hepatology</i> , 2013, 58, 1105-1110. | 3.6 | 105 |
| 4 | Portal myofibroblasts promote vascular remodeling underlying cirrhosis formation through the release of microparticles. <i>Hepatology</i> , 2015, 61, 1041-1055. | 3.6 | 102 |
| 5 | Functions of the Gallbladder. , 2016, 6, 1549-1577. | | 99 |
| 6 | Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2020, 72, 627-635. | 1.8 | 84 |
| 7 | A functional classification of ABCB4 variations causing progressive familial intrahepatic cholestasis type 3. <i>Hepatology</i> , 2016, 63, 1620-1631. | 3.6 | 81 |
| 8 | Distinct proteomic features of two fibrogenic liver cell populations: Hepatic stellate cells and portal myofibroblasts. <i>Proteomics</i> , 2010, 10, 1017-1028. | 1.3 | 56 |
| 9 | Effects of Cellular, Chemical, and Pharmacological Chaperones on the Rescue of a Trafficking-defective Mutant of the ATP-binding Cassette Transporter Proteins ABCB1/ABCB4. <i>Journal of Biological Chemistry</i> , 2012, 287, 5070-5078. | 1.6 | 47 |
| 10 | Phosphorylation of ABCB4 impacts its function: Insights from disease-causing mutations. <i>Hepatology</i> , 2014, 60, 610-621. | 3.6 | 43 |
| 11 | Simple Magnetic Resonance Scores Associate With Outcomes of Patients With Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2785-2792.e3. | 2.4 | 43 |
| 12 | Functional defect of variants in the adenosine triphosphate-binding sites of ABCB4 and their rescue by the cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor (VX-770). <i>Hepatology</i> , 2017, 65, 560-570. | 3.6 | 40 |
| 13 | Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018, 42, 521-528. | 0.7 | 40 |
| 14 | Portal myofibroblasts connect angiogenesis and fibrosis in liver. <i>Cell and Tissue Research</i> , 2016, 365, 583-589. | 1.5 | 32 |
| 15 | Targeted pharmacotherapies for defective ABC transporters. <i>Biochemical Pharmacology</i> , 2017, 136, 1-11. | 2.0 | 31 |
| 16 | Portal fibroblasts with mesenchymal stem cell features form a reservoir of proliferative myofibroblasts in liver fibrosis. <i>Hepatology</i> , 2022, 76, 1360-1375. | 3.6 | 30 |
| 17 | Diet-Induced Dysbiosis and Genetic Background Synergize With Cystic Fibrosis Transmembrane Conductance Regulator Deficiency to Promote Cholangiopathy in Mice. <i>Hepatology Communications</i> , 2018, 2, 1533-1549. | 2.0 | 28 |
| 18 | Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1117-1127. | 1.9 | 28 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | The Complementary Value of Magnetic Resonance Imaging and Vibration-Controlled Transient Elastography for Risk Stratification in Primary Sclerosing Cholangitis. <i>American Journal of Gastroenterology</i> , 2019, 114, 1878-1885. | 0.2 | 24 |
| 20 | Low-phospholipid-associated cholelithiasis syndrome: Prevalence, clinical features, and comorbidities. <i>JHEP Reports</i> , 2021, 3, 100201. | 2.6 | 24 |
| 21 | ABCB4: Insights from pathobiology into therapy. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014, 38, 557-563. | 0.7 | 22 |
| 22 | Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma. <i>Journal of Experimental Medicine</i> , 2021, 218, . | 4.2 | 20 |
| 23 | Role of Angiogenesis in the Pathogenesis of NAFLD. <i>Journal of Clinical Medicine</i> , 2021, 10, 1338. | 1.0 | 19 |
| 24 | Expression patterns of nuclear receptors in parenchymal and non-parenchymal mouse liver cells and their modulation in cholestasis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017, 1863, 1699-1708. | 1.8 | 18 |
| 25 | Novel defatting strategies reduce lipid accumulation in primary human culture models of liver steatosis. <i>DMM Disease Models and Mechanisms</i> , 2020, 13, . | 1.2 | 18 |
| 26 | Up-regulation of miR-34b/c by JNK and FOXO3 protects from liver fibrosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, . | 3.3 | 16 |
| 27 | LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 308-320. | 1.9 | 15 |
| 28 | Endoplasmic reticulum stress induces inverse regulations of major functions in portal myofibroblasts during liver fibrosis progression. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 3688-3696. | 1.8 | 13 |
| 29 | Structural analogues of roscovitine rescue the intracellular traffic and the function of ER-retained ABCB4 variants in cell models. <i>Scientific Reports</i> , 2019, 9, 6653. | 1.6 | 12 |
| 30 | Culture Model of Rat Portal Myofibroblasts. <i>Frontiers in Physiology</i> , 2016, 7, 120. | 1.3 | 11 |
| 31 | Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. <i>PLoS ONE</i> , 2020, 15, e0242306. | 1.1 | 10 |
| 32 | Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity. <i>BMJ Open</i> , 2015, 5, e010017. | 0.8 | 9 |
| 33 | A PDZ-Like Motif in the Biliary Transporter ABCB4 Interacts with the Scaffold Protein EBP50 and Regulates ABCB4 Cell Surface Expression. <i>PLoS ONE</i> , 2016, 11, e0146962. | 1.1 | 9 |
| 34 | Cholangiopathy aggravation is caused by VDR ablation and alleviated by VDR-independent vitamin D signaling in ABCB4 knockout mice. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 166067. | 1.8 | 9 |
| 35 | Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 998-1007. | 0.8 | 8 |
| 36 | A systemic mechanism of increased transendothelial migration of leukocytes through the blood-brain barrier in hepatic encephalopathy. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101801. | 0.7 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. <i>JHEP Reports</i> , 2021, 3, 100298. | 2.6 | 6 |
| 38 | Effect of CFTR correctors on the traffic and the function of intracellularly retained ABCB4 variants. <i>Liver International</i> , 2021, 41, 1344-1357. | 1.9 | 4 |
| 39 | RAB10 Interacts with ABCB4 and Regulates Its Intracellular Traffic. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7087. | 1.8 | 3 |
| 40 | ATP-binding cassette transporters expression in rats with cirrhosis and hepatic encephalopathy. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101784. | 0.7 | 2 |
| 41 | Editorial: simplifying screening for primary liver cancer - do the LCR1 and LCR2 tests hold the key? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 613-614. | 1.9 | 0 |
| 42 | Editorial: Immunity from trigger to therapy in hepatobiliary diseases. <i>Current Opinion in Gastroenterology</i> , 2021, 37, 77-78. | 1.0 | 0 |
| 43 | Editorial: Clinical and pathogenic novelties in cholangiopathies: new treatments and many more to come. <i>Current Opinion in Gastroenterology</i> , 2022, 38, 81-82. | 1.0 | 0 |